Structured evidence table for Choline Mood Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Choline Mood Randomized Trial | This review synthesizes current evidence on the effects of both plant- and animal-derived foods on cognitive outcomes from early development through older adulthood. | 4 | Hardaway C (2026) | Brain Foods: A Narrative Review of Food Items and Their Impact on Cognition over the Life Course. |
| Choline Mood Randomized Trial | Evidence was evaluated across life stages, considering nutrient bioavailability, dietary patterns, and the interplay between structural, socioeconomic, and environmental factors that influence access to these foods. | 4 | Hardaway C (2026) | Brain Foods: A Narrative Review of Food Items and Their Impact on Cognition over the Life Course. |
| Choline Mood Randomized Trial | In early childhood, eggs, meat, and nuts were linked to improved neurodevelopment and reductions in developmental delays, while evidence for seafood and dairy was more mixed. | 4 | Hardaway C (2026) | Brain Foods: A Narrative Review of Food Items and Their Impact on Cognition over the Life Course. |
| Choline Mood Randomized Trial | Background/Objectives : Cognitive function is fundamental to daily life, and nutrition is a key modifiable determinant of brain health across the lifespan. | 4 | Hardaway C (2026) | Brain Foods: A Narrative Review of Food Items and Their Impact on Cognition over the Life Course. |
| Choline Mood Randomized Trial | Although L-α-GPC has been discussed in both neurodegenerative and vascular-related cognitive disorders, the available evidence remains heterogeneous. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
| Choline Mood Randomized Trial | Therefore, a careful and contextualized interpretation of the literature is necessary, particularly when comparing evidence across Alzheimer’s disease, Parkinson’s disease-related cognitive decline, and cognitive impairment associated with cerebrovascular conditions. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
| Choline Mood Randomized Trial | Given this background, the present narrative review focuses primarily on the mechanistic and clinical evidence regarding L-α-GPC in cognitive decline associated with neurodegenerative disorders, while also acknowledging relevant findings from studies of vascular- or cerebrovascular-related cognitive impairment where appropriate. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
| Choline Mood Randomized Trial | 1 2 Neurodegeneration involves the progressive loss of neuronal structure and function, leading to cognitive and motor impairments. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
Source documents